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EFS was significantly longer in the Dex/Thal arm (median, 44 vs. 
12 months; P = .0021).Complete response on serum electrophoresis 
was achieved in 4/13 patients. Two presented a TE (0/30 in the 
control arm). Otherwise, tolerability of maintenance Dex/Thal 
(median duration 17 months) was acceptable. Within a median 
follow-up of 39 months, 3-year OS were 73% and 72% (P = .66) 
since first randomization and estimated at 64% and 74% (P = .52) 
after maintenance randomization. In combination with alkylating 
agents, oral Dex/Thal is an effective induction regimen in elderly 
MM patients. When administered as an intermittent maintenance 
treatment, it has a good safety profile and significantly prolongs 
EFS, but does not significantly improve OS.
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Baseline free light chain (FLC) values and their ratio (FLCR) 
were shown valuable for the prognostication of survival in MM. 
The underlying biologic mechanisms of FLC hypersecretion by 
malignant plasma cells are unknown and it could be assumed 
that molecular or microenvironmental factors are involved. 
Numerous cytokines secreted mostly by the bone marrow 
microenvironmental cells participate in MM pathogeny. The 
purpose of the present study was to determine the baseline serum 
levels of such cytokines, namely IL-6 and its soluble receptor (sIL-
6R), syndecan-1 and its cleaved soluble form (s-synd-1), VEGF 
and BLyS, and to investigate any possible correlation of their 
levels with FLC values. 152 MM patients were studied (derived 
from a series of 245 patients with FLCs measured at diagnosis). 
50% of patients were males, 25% were in Durie-Salmon stage 
I, 33% stage II, and 42% stage III respectively. 33% were ISS 
stage I, 25% stage II and 42% stage III respectively. 15% of the 
patients had impaired renal function, 32% presented anemia and 
4% thrombocytopenia. LDH and CRP were abnormal in 15% 
and 48% respectively. FLCs were measured by nephelometry 
(FREELITE, The Binding Site Ltd. Birmingham, UK). The light 
chain ratio (sFLCR) κ/λ or λ/κ was built with the uninvolved 
LC as denominator and values over the median were defined as 
high. Statistical analysis was performed by standard methods. S-
synd-1, VEGF, IL-6, sIL-6R and BLyS were measured in 98, 80, 
81, 92, and 79 patients respectively with available frozen serum 
aliquots at diagnosis. Measurements were performed by ELISA, in 
duplicate (Diaclone Research’s kit for s-synd-1 and R&D Systems’ 
for the rest). The median sFLCR was 8 for κ-MM patients and 
50.5 for λ-MM. High sFLCR values correlated with s-synd-1 (P = 
.012) while no correlation was found with VEGF (P = .08), IL-6 
(P = .61), sIL-6R (P = .9) and BLyS (P = .83). Prognostic impact 
with regard to patients’ survival was observed for baseline sFLCR, 
serum s-synd-1, sIL-6R and BLyS. The prognostic implication 
of sFLCR was independent of sIL-6R and BLyS by multivariate 
analysis. In conclusion, the correlation between sFLCR and serum 
s-syndecan may suggest that the last could play a role in the 
inappropriate FLC secretion.
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Multiple myeloma (MM) is characterized by proliferation of 
plasma cell, and IL-6 is essential growth factor of myeloma cell. 
IL-6 play a key role through IL-6 receptor, which is located in 
the long arm of chromosome 1 (1q). Gain of 1q is one of the 
most frequent cytogenetic changes in myeloma. We hypothesized 
increased expression of IL-6R in myeloma cells gives a growth 
previlage to myeloma cells among bone marrow hematopoietic 
cells. We investigated the frequency of the amplification of 
IL-6 receptor gene among 144 newly diagnosed MM patients. 
Amplification of IL-6R was assessed by interphase FICTION 
method using IL-6R probe and anti-light chain antibody with 
bone marrow nucleated cells. In context with IL-6R, interphase 
FISH for 1q (1q21), Rb1 (13q14) deletion, IGH translocation 
and numerical changes of chromosome (chromosome 9,17,20) 
was performed. We detected IL-6R amplification in 65% (66/102) 
of the multiple myeloma patients using IL-6R FISH. Using Rb1 
(13q14) FISH probes, 93% (28/30) of patients were identified 
as having genetic changes. Similarly, using IgH (14q32), 1q25 
and TP53 (17p13.1) FISH probes, 48% (49/102), 43% (31/72) 
and 18% (9/50) of patients were found to have genetic changes. 
Several poor-risk genetic features, such as low albulin level, 
positive IGH FISH result and positive TP53 FISH results were 
significantly associated with IL-6R amplification. We suggest that 
amplification of IL-6R in myeloma cells may contribute to the 
proliferation of myeloma cells and is associated with poor prognosis 
in myeloma patients. 
